Citius Oncology, Inc.
- CTOR
- NASDAQ
- Medical - Pharmaceuticals
- Targeted Cancer Drugs
- Orphan Drug Development
$0.71
Today −7.49%Quote Oct 19, 2026, 08:00 PM UTC
−24.72%over the last month
Max drawdown −34.6%From 1-month high −32.6%3 months +34.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Citius Oncology
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Employees
285
Market value
$66.1M
Quote Oct 19
Analyst target
$6.00
+744.6% from here
Floor
$0.66
7.4% below price
Resistance
$0.73
2.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CTORPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free